Covaxin effective against symptomatic Covid : The Indian corona vaccine ‘Covaxin’ is 50% effective in protecting against coronavirus with severe symptoms. This claim has been made in Bharat Biotech’s first real assessment of the efficacy of Covaxin, which is called ‘The Lancet Infectious Disease’. published Has been done. This assessment has been done on the basis of a study done on 2714 health workers working in AIIMS, Delhi during the peak of second wave of corona in the country (ie between 15 April 2021 to 15 May 2021). Researchers said that during the study, there was an outbreak of delta variant of the virus in India and then this variant was responsible for 80 percent of the total confirmed cases of Kovid-19. According to Manish Soneja, Additional Professor of Medicine at AIIMS, New Delhi, “Our study shows a complete picture about how BBV152 (Covaccine) works in this area. This should be considered in the backdrop of increasing cases of Kovid-19 in India and the escape potential of the delta form vaccine.
From January 16 this year, all the 23,000 personnel were specially provided with the vaccine at the Kovid Vaccine Center at AIIMS. Researchers assessed the vaccine’s effectiveness against symptomatic SARS-CoV-2 infection.
How did the study happen?
Of the 2,714 employees involved in the study, 1,617 people were confirmed to have SARS-CoV-2 and 1,097 were diagnosed with no infection.
2 year old son had incurable disease, father prepared medicine by making lab at home
This study revealed that two doses of Covaxin vaccine resulted in 50 percent protection against symptomatic COVID-19 disease, with an RT-PCR test performed 14 or more days after the second dose. According to the researchers, the effect of both the doses remained in the 7-week follow-up process.
what the experts say
Parul Kodan, assistant professor of medicine at AIIMS, said, “The results of the study confirm other earlier studies which said that BBV152 (BBV) is the most important preventive measure. 152) are needed.
You can’t sleep? Many serious problems found in the survey among those who do not sleep
Know about Covaccine
Bharat Biotech of Hyderabad, in collaboration with the National Institute of Virology, Pune, of the Indian Council of Medical Research, manufactured Covaxin, which was administered 2 times at an interval of 28 days. It is given in dosage. Covaxin was approved for emergency use in India in January for people aged 18 years and above. The World Health Organization (WHO) this month included the vaccine in the list of approved vaccines for emergency use of Kovid-19 vaccines.
Tags: coronavirus, Health, Health News